uniQure (NASDAQ:QURE) Shares Gap Down - Here's What Happened

Shares of uniQure N.V. (NASDAQ:QURE - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $14.50, but opened at $13.72. uniQure shares last traded at $14.35, with a volume of 428,161 shares trading hands.

Analysts Set New Price Targets

Several equities analysts have weighed in on QURE shares. Chardan Capital reissued a "buy" rating and set a $38.00 price target on shares of uniQure in a research report on Friday, May 30th. Guggenheim reiterated a "buy" rating and set a $28.00 price objective on shares of uniQure in a research report on Monday, May 12th. HC Wainwright restated a "buy" rating and issued a $70.00 target price on shares of uniQure in a report on Thursday, May 29th. Cantor Fitzgerald upgraded shares of uniQure to a "strong-buy" rating in a report on Monday, May 19th. Finally, Wall Street Zen downgraded shares of uniQure from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $37.82.

uniQure Stock Performance

The company has a quick ratio of 11.99, a current ratio of 11.99 and a debt-to-equity ratio of 1.53. The company has a market cap of $827.73 million, a PE ratio of -3.44 and a beta of 0.08. The stock's 50 day simple moving average is $14.91 and its two-hundred day simple moving average is $13.72.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.25. The firm had revenue of $1.57 million for the quarter, compared to analyst estimates of $5.93 million. uniQure had a negative net margin of 1,077.05% and a negative return on equity of 483.87%. As a group, research analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current year.

Insider Buying and Selling

In other uniQure news, Director Rachelle Suzanne Jacques sold 2,112 shares of the business's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the transaction, the director owned 28,346 shares in the company, valued at $409,599.70. The trade was a 6.93% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director David D. Meek sold 2,112 shares of the stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the completion of the transaction, the director directly owned 34,190 shares of the company's stock, valued at $494,045.50. This represents a 5.82% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,144 shares of company stock valued at $322,426. 4.79% of the stock is owned by insiders.

Institutional Investors Weigh In On uniQure

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Tudor Investment Corp ET AL raised its stake in shares of uniQure by 5.9% in the 4th quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company's stock valued at $438,000 after purchasing an additional 1,371 shares in the last quarter. Wells Fargo & Company MN increased its holdings in uniQure by 13.9% in the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after buying an additional 1,503 shares during the last quarter. Northern Trust Corp raised its stake in uniQure by 2.1% during the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock valued at $1,688,000 after buying an additional 1,923 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in uniQure by 6.0% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company's stock valued at $1,253,000 after buying an additional 3,996 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in uniQure during the 2nd quarter worth approximately $117,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.